Gene Expression Profiles Can Predict Panitumumab Monotherapy Responsiveness in Human Tumor Xenograft Models

Por Boedigheimer, Michael J, Freeman, Daniel J, Kiaei, Panteha, Damore, Michael A, Radinsky, Robert
Publicado em 2013

Augmentation of radiation response by panitumumab in models of upper aerodigestive tract cancer

Por Kruser, Tim J., Armstrong, Eric A., Ghia, Amol J., Huang, Shyhmin, Wheeler, Deric L., Radinsky, Robert, Freeman, Daniel J., Harari, Paul M.
Publicado em 2008

A comparability study of 5 commercial KRAS tests

Por Oliner, Kelly, Juan, Todd, Suggs, Sid, Wolf, Michael, Sarosi, Ildiko, Freeman, Daniel J, Gyuris, Tibor, Baron, Will, Bakker, Andreas, Parker, Alex, Patterson, Scott D
Publicado em 2010

Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer

Por Freeman, Daniel J, McDorman, Kevin, Ogbagabriel, Selam, Kozlosky, Carl, Yang, Bing-Bing, Doshi, Sameer, Perez-Ruxio, Juan Jose, Fanslow, William, Starnes, Charlie, Radinsky, Robert
Publicado em 2012

Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced...

Por Mendell, Jeanne, Freeman, Daniel J., Feng, Wenqin, Hettmann, Thore, Schneider, Matthias, Blum, Sabine, Ruhe, Jens, Bange, Johannes, Nakamaru, Kenji, Chen, Shuquan, Tsuchihashi, Zenta, von Pawel, Joachim, Copigneaux, Catherine, Beckman, Robert A.
Publicado no EBioMedicine (2015)